Infertility Drugs Market

The global Infertility Drugs Market is projected to grow from USD 4.1 Bn in 2026 to USD 6.4 Bn by 2033, registering a CAGR of 6%.

Remarkably Dropping Fertility Rates Necessitate Effective Infertility Treatment Worldwide

According to WHO, infertility is a global health issue affecting millions of people of reproductive age worldwide. Available data suggests that between 48 million couples and 186 million individuals have infertility globally. Infertility may occur due to male factors, female factors, a combination of male and female factors or may be unexplained. For both women and men, however, environmental and lifestyle factors such as smoking, excessive alcohol intake, obesity, and exposure to environmental pollutants have been associated with lower fertility rates. This remains the primary factor driving the growth of infertility drugs market. Fertility medications are a regular and normal part of infertility treatments and the in-vitro fertilisation (IVF) procedure. These medications are used to prepare the body for treatment and to increase the probability that more healthy eggs are released from the ovaries. Factors such as decreased fertility rates, an increase in the number of fertility clinics globally, technological developments, and increased public-private partnerships, funding, and grants will continue to fuel the progress of infertility treatment space, thereby shaping the infertility drugs market.

Increased Prevalence of Lifestyle Disorders Underpins Market Growth

Increased public investment in medication development, and faster drug approvals from various regulatory authorities drive infertility drugs market expansion. Infertility is becoming more common as poor diet, and common lifestyle problems like stress, smoking, obesity, diabetes, and polycystic ovarian syndrome (PCOS) rise, increasing the demand for infertility medicines. Money, job, and the economy are the most often mentioned sources of stress. Fears about job security are on the rise, causing widespread worry. Recent research has discovered correlations between women's and men’s daily stress levels and lower odds of pregnancy. Women with high alpha-amylase levels took 29 percent longer to become pregnant than those with lower levels. Similarly, men with increased stress produced less testosterone, affecting fertility. In 2020, about 190 million people reported much higher stress levels than in previous years. The increased stress induction in human beings will affect their fertility, increasing the demand for infertility drugs.

Another factor responsible for increasing infertility is the growing number of lifestyle disorders. Cardiovascular diseases like hypertension, heart attack, stroke, and diabetes are the most frequent lifestyle conditions. The primary cause of the rising diabetes prevalence are factors such as obesity, age, ethnicity, lifestyle, socioeconomic level, education, and urbanisation. Diabetes has been linked to lower fertility and reproductive health in men and women. Diabetes can affect hormones, resulting in delayed or unsuccessful implantation and fertilisation. Diabetes is expected to affect roughly 283,000 Americans under the age of 20, accounting for approximately 35% of that group. The continual increase in the number of diabetics in the young population will propel the use of infertility drugs in the coming years.

Demand for Female Infertility Treatment Remains Prominent

In the forecast period, the female infertility treatment segment will hold the highest proportion of the infertility drugs market by patient type. Female fertility rates are declining, and the availability of numerous fertility treatment options and the growing number of fertility facilities around the world are driving the expansion of the female infertility treatment market. The segment's profitable growth can be due to rising infertility rates and misinformation (women are compared to men). The most common reason for infertility in women is an increasing prevalence of thyroid-related disorders, and breast cancer, which necessitates more radiation exposure, resulting in a dramatic fall in the fertility rate. Higher demand is caused by an increase in smoking and alcohol usage and the prevalence of various illnesses such as PCOS, and uterine fibroids. This element is projected to propel the segment's expansion.

North American Market Leads the Pack, Asia Pacific Grows Significant

North America is expected to dominate the worldwide infertility medications market during the projected period. This dominance is primarily due to rising menopausal illnesses, urinary infections, thyroid difficulties, endometriosis, and other conditions caused by women's hectic lifestyles, and increased stress levels. According to one of the Centers for Disease Control and Prevention (CDC) research studies published in 2019, PCOS affects around 6-12% of women of reproductive age, totalling more than 5 million people. A significant increase in oligozoospermia, varicocele, diabetes, and other conditions among men in the US pushes the region's revenue share. The existence of a more significant number of reproductive endocrinologists, as well as improved healthcare infrastructure, drives the expansion of infertility drugs market in the US. Government spending on women's healthcare awareness, increasing the geriatric female population, and early product releases are projected to contribute to the country's dominant position in the worldwide market.

Asia Pacific also remains an important infertility drugs market. Significant increase in medical tourism, increased awareness of the availability of infertility treatment procedures, expanding fertility centres in the region, rising healthcare expenditures, increasing rate of infertility in the area, and government initiatives to increase the accessibility of infertility treatment in emerging nations. India currently operates 1750+ fertility centre facilities and hospitals, doing an average of 250,000 cycles each year, with a substantial concentration in big cities. Growing number of fertility centres in the country will drive the region’s infertility drugs market ahead. The market has expanded due to excellent surrogacy and egg/sperm donation knowledge. The rise in the median age of first-time motherhood is fuelling market development, as women prioritise their careers before becoming mothers for the first time. Most women suffer from various gynaecological diseases due to their sedentary and fast-paced lifestyle, which further reduces their chances of conceiving naturally and contributes to the growth of the Asia Pacific infertility drugs market.

Global Infertility Drugs Market: Competitive Landscape

• Merck & Co., Inc.
• Ferring B.V.
• Organon Group of Companies
• Abbott
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Mankind Pharma
• Teva Pharmaceutical Industries LTD.
• Sanofi

Global Infertility Drugs Market is Segmented as Below:

By Drug Class

• Gonadotropin
• Aromatase Inhibitors
• Selective Oestrogen Receptor Modulators (SERMs)
• Biguanides
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By End User

• Male
• Female

By Region

• North America
• Europe
• Latin America
• East Asia
• The Middle East & Africa
• South Asia & Pacific